Eagle Pharmaceuticals have just announced the success of a Phase 1 trial of 81 patients, which has shown that a 50ml admixture of Bendamustine HCl delivered in ten minutes (their rapidly infused product) was found to be bioequivalent to the Treanda 500mL admixture, which requires a 60-minute infusion. Their goal is to bring their rapidly infused product to market as soon as possible.
Eagle received orphan drug designation for its rapidly infused product for CLL and indolent B-cell non-Hodgkin’s lymphoma on July 2, 2014.
So if you find next year that you are given a smaller volume of Bendamustine and are done in 10 minutes or so rather than over an hour like you were used to, don't panic. You might be getting this low volume, rapidly infused version.